环孢素A与地夸磷索钠滴眼液治疗干眼症后泪液蛋白质组变化比较
本研究纳入18例非干燥综合征干眼症患者,分别接受0.05%环孢素A或3%地夸磷索钠滴眼液治疗4周,比较泪液蛋白质组与临床指标变化。共鉴定794种蛋白质,两组分别发现54和106种差异表达蛋白,均涉及免疫应答与细胞解毒通路上调,但激活的泪液特异性生物标志物显著不同。
要点
- 两种药物均改善临床参数,但激活的泪液生物标志物差异显著
- 环孢素A组鉴定54种差异表达蛋白,地夸磷索钠组106种
- 差异蛋白主要富集于先天性与适应性免疫应答及细胞解毒过程
核心结论
- 两种药物均改善干眼症临床参数,但泪液特异性生物标志物激活谱显著不同。
- 鉴定的差异表达蛋白及与临床参数相关的蛋白可能成为干眼症候选生物标志物。
研究设计与样本
- 共纳入18例非干燥综合征干眼症患者,每组9例,分别接受0.05%环孢素A或3%地夸磷索钠滴眼液治疗4周。
- 治疗前后评估泪膜破裂时间、角膜与结膜染色及Schirmer试验1,并采用液相色谱质谱法表征泪液蛋白质组。
- 差异表达蛋白定义为倍数变化>1.5或<0.67且P<0.05。
主要发现
- 共鉴定794种蛋白质,治疗前后总体无显著差异。
- 环孢素A组与地夸磷索钠组分别鉴定54种和106种差异表达蛋白。
- 基因本体分析显示两种治疗均增强先天性与适应性免疫应答及细胞解毒。
- 蛋白网络分析显示免疫应答相关炎症是两组治疗过程的主要机制。
关键数值与推荐
- 差异表达蛋白判定标准为倍数变化>1.5或<0.67且P<0.05。
- 共鉴定794种蛋白质,环孢素A组54种差异表达蛋白,地夸磷索钠组106种。
临床怎么用
- 两种药物临床均有效,但泪液蛋白标志物谱不同,提示可根据生物标志物谱选择个体化治疗。
- 鉴定的差异表达蛋白可能作为评估干眼症严重程度与治疗效果的候选生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the changes in human tear proteome and clinical effects following topical cyclosporine A (CsA) 0.05% or diquafosol tetrasodium (DQS) 3% treatment of dry eye disease (DED), and to identify biomarkers for determining disease severity and treatment effectiveness in DED. METHODS: A total of 18 patients were diagnosed with non-Sjögren DED. Nine patients in each group were treated with topical CsA 0.05% or DQS 3% for 4 weeks. Tear samples were collected after evaluation of tear breakup time, corneal and conjunctival erosion staining, and results of Schirmer's test 1 before and after treatment. Proteomes were characterized using liquid chromatography mass spectrometry, and proteins exhibiting a fold change >1.5 or <0.67 (P < 0.05) were considered differentially expressed (DEP). RESULTS: A total of 794 proteins were identified, with no significant difference observed between pretreatment and posttreatment conditions. Proteomic analysis identified 54 and 106 DEPs between treatment groups (CsA and DQS, respectively), with gene ontology analysis indicating that both treatments enhanced innate and adaptive immune responses and cellular detoxification. Protein-network analysis showed that inflammation associated with the immune response was primarily responsible for the therapeutic process in both groups. CONCLUSIONS: These results provide insight into the broad scope of changes at the ocular surface in DED and indicated that although both drugs improved the clinical parameters, the activated tear-specific biomarkers differed significantly between treatments. Our findings suggest that the DEPs identified here and those correlated with the clinical parameters might represent candidate biomarkers for DED.
引用
- Ji YW, Kim HM, Ryu SY, et al. Changes in Human Tear Proteome Following Topical Treatment of Dry Eye Disease: Cyclosporine A Versus Diquafosol Tetrasodium. Invest Ophthalmol Vis Sci. 2019. PMID: 31800960. doi:10.1167/iovs.19-27872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。